Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Boerner, Julie L ^a   Nechiporchik, Nicole ^a   Mueller, Kelly L ^a   Polin, Lisa ^a   Heilbrun, Lance ^a   Boerner, Scott A ^a,b   Zoratti, Gina L ^a   Stark, Karri ^a   LoRusso, Patricia M ^a,b   Burger, Angelika ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; H2AX GAMMA PROTEIN; HISTONE H2AX; IRINOTECAN; UNCLASSIFIED DRUG; VELIPARIB; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; CAMPTOTHECIN; DNA BINDING PROTEIN; DNA TOPOISOMERASE INHIBITOR; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PARP1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL DEATH; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG PROTEIN BINDING; ENZYME INHIBITION; EXCISION REPAIR; GENE MUTATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; ANALOGS AND DERIVATIVES; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DNA-BINDING PROTEINS; DRUG SYNERGISM; ENDONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; POLY (ADP-RIBOSE) POLYMERASE-1; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; TOPOISOMERASE I INHIBITORS; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925245032     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119614     Document Type: Article

References (27)

1. Korsching E, Jeffrey SS, Meinerz W, Decker T, Boecker W, Buerger H. Basal carcinoma of the breast revisited: An old entity with new interpretations. Journal of Clinical Pathology 2008; 61: 553-560. doi: 10.1136/jcp.2008.055475 PMID: 18326009
2. Santana-Davila R, Perez EA. Treatment options for patients with triple-negative breast cancer. J Hematol Oncol 2010; 3: 42. doi: 10.1186/1756-8722-3-42 PMID: 20979652
3. Chacon RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res 2010; 12 Suppl 2: S3. doi: 10.1186/bcr2574 PMID: 21050424
4. Starita LM, Parvin JD. The multiple nuclear functions of BRCA1: Transcription, ubiquitination and DNA repair. Current Opinion in Cell Biology 2003; 15: 345-350. PMID: 12787778
5. Xu J, Wang B, Zhang Y, Li R, Wang Y, Zhang S. Clinical implications for BRCA gene mutation in breast cancer. Molecular Biology Reports 2012; 39: 3097-3102. doi: 10.1007/s11033-011-1073-y PMID: 21691706
6. Institute NC. PDQ Genetics of Breast and Ovarian Cancer. Bethesda, MD: National Cancer Institute.
7. Murphy CG, Moynahan ME. BRCA Gene Structure and Function in Tumor Suppression: A Repair- Centric Perspective. The Cancer Journal 2010; 16: 39-47 doi: 10.1097/PPO.0b013e3181cf0204 PMID: 20164689
8. Thomas H. The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings. Molecular Oncology 2011; 5: 387-393. doi: 10.1016/j.molonc.2011.07.001 PMID: 21821475
9. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004; 26: 882-893. PMID: 15273990
10. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007; 13: 1383-1388. PMID: 17332279
11. Graziani G, Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol Res 2005; 52: 109-118. PMID: 15911339
12. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134. doi: 10.1056/ NEJMoa0900212 PMID: 19553641
13. Rasheed ZA, Rubin EH. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 2003; 22: 7296-7304. PMID: 14576839
14. Wang JC. Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol 2002; 3: 430-440. PMID: 12042765
15. Barnabas N, Cohen D. Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines. Int J Breast Cancer 2013; 2013: 872743. doi: 10.1155/2013/872743 PMID: 23401782
16. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440-446. doi: 10.1158/0008-5472.CAN-09-1947 PMID: 20068163
17. Corbett TH, LoRusso P, Demchick L, Simpson C, Pugh S, White K, et al. Preclinical antitumor efficacy of analogs of XK469: Sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate. Invest New Drugs 1998; 16: 129-139. PMID: 9848576
18. Littell RC, Milliken GA, Stroup WW, Wolfinger RD, Schabenberger O (2006) Statistical Analysis System (SAS) for Mixed Models. Cary, NC: SAS Institute Inc.
19. Holm S, Wahlin A. Identification of renal tubular epithelial cells in urine with immunofluorescence. Acta Med Scand 1979; 205: 587-591. PMID: 112837
20. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2- deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-917. PMID: 15829966
21. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921. PMID: 15829967
22. Tutt AN, Lord CJ, McCabe N, Farmer H, Turner N, Martin NM, et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 2005; 70: 139-148. PMID: 16869747
23. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991. PMID: 16957145
24. Ciccia A, McDonald N, West SC. Structural and functional relationships of the XPF/MUS81 family of proteins. Annu Rev Biochem 2008; 77: 259-287. doi: 10.1146/annurev.biochem.77.070306.102408 PMID: 18518821
25. Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 2007; 33: 565-577. PMID: 17707593
26. Zhang YW, Regairaz M, Seiler JA, Agama KK, Doroshow JH, Pommier Y. Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res 2011; 39: 3607-3620. doi: 10.1093/nar/gkq1304 PMID: 21227924
27. Anders CK, Deal AM, Miller CR, Khorram C, Meng H, Burrows E, et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 2011; 117: 1602-1611. doi: 10.1002/cncr.25746 PMID: 21472708